Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease

Via Peters

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) — Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today they will be pursuing the 505(b)(2) pathway for its investigational agent, H-100™, a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, a condition impacting more […]

Petros Pharmaceuticals Announces $7.5 Million Offering

Via Peters

  NEW YORK, Dec. 22, 2021 /PRNewswire/ — Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today announced that it has entered into definitive agreements with the company’s largest investor and other existing investors, for the purchase and sale of 2,186,589 shares of Petros Pharmaceuticals’ common […]